Sublethal exposure to alpha radiation ((223)Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation

Radium-223 dichloride (Xofigo(®); (223)Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases in patients with advanced castration-resistant prostate cancer. It is also being examined clinically in patients with breast and lung carcinoma and patients with mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Malamas, Anthony S., Gameiro, Sofia R., Knudson, Karin M., Hodge, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341329/
https://www.ncbi.nlm.nih.gov/pubmed/27893426
http://dx.doi.org/10.18632/oncotarget.13520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341329/
https://www.ncbi.nlm.nih.gov/pubmed/27893426
http://dx.doi.org/10.18632/oncotarget.13520

Ejemplares similares